CorMedix Sees 81% Upside with $14 Price Target from Royal Bank Of Canada

CorMedix (NASDAQ:CRMD) has received an upgraded price target of $14.00 from Royal Bank Of Canada, representing a potential upside of 81.11% from its current price.

This increase comes after the company reported Q2 revenue of $101.9 million, exceeding analyst expectations, and adjusted EBITDA reached $58.7 million, while net income was $26.0 million.

CorMedix's management maintained its FY 2026 revenue outlook of $325 million to $345 million and raised adjusted EBITDA guidance, reinforcing expectations for strong profitability and operating leverage.

The company is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures, in addition to its lead asset Neutrolin, a catheter lock solution that prevents catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis.